Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Oct 05, 2023 3:12pm
93 Views
Post# 35671720

RE:RE:RE:RE:The Brazil contract is actually around $150 million for LABS

RE:RE:RE:RE:The Brazil contract is actually around $150 million for LABSOkay, lets normalize out of the equation Brazil as the revenue generator.  Q1 2024 profitability is Mr. Pidduck's quantum leaps and assumptions and I'm only working from that along with the given financial data.   We still need a contract of approximately $150 million for Q1 at approx 21% gross margins to generate a penny per share in earnings.  Pidduck is leaving slices of bread not bread crumbs.   "traditional global pharmceutical partner'  and 'secrecy for competitive reasons'.   Those two alone for me are a loaf of bread.  

Time will tell the Truth π.  It always does when you fully appreciate what the essence of 'time' is and it's origin.  
<< Previous
Bullboard Posts
Next >>